These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 30142012)

  • 1. Neprilysin inhibition in mouse islets enhances insulin secretion in a GLP-1 receptor dependent manner.
    Esser N; Barrow BM; Choung E; Shen NJ; Zraika S
    Islets; 2018; 10(5):175-180. PubMed ID: 30142012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neprilysin inhibition improves intravenous but not oral glucose-mediated insulin secretion via GLP-1R signaling in mice with
    Esser N; Mongovin SM; Parilla J; Barrow BM; Mundinger TO; Fountaine BS; Larmore MJ; Castillo JJ; Akter R; Hull RL; Zraika S
    Am J Physiol Endocrinol Metab; 2022 Mar; 322(3):E307-E318. PubMed ID: 35128957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Inhibition of Intestinal Neprilysin Enhances Insulin Secretion via GLP-1 Receptor Signaling in Male Mice.
    Esser N; Mundinger TO; Barrow BM; Zraika S
    Endocrinology; 2023 Mar; 164(5):. PubMed ID: 36964914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes.
    Omar BA; Liehua L; Yamada Y; Seino Y; Marchetti P; Ahrén B
    Diabetologia; 2014 Sep; 57(9):1876-83. PubMed ID: 24939431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
    Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
    Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY.
    Guida C; McCulloch LJ; Godazgar M; Stephen SD; Baker C; Basco D; Dong J; Chen D; Clark A; Ramracheya RD
    Diabetes Obes Metab; 2018 Mar; 20(3):571-581. PubMed ID: 28892258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels.
    Willard JR; Barrow BM; Zraika S
    Diabetologia; 2017 Apr; 60(4):701-708. PubMed ID: 27933334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
    Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
    Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for neural contribution to islet effects of DPP-4 inhibition in mice.
    Ahlkvist L; Omar B; Pacini G; Ahrén B
    Eur J Pharmacol; 2016 Jun; 780():46-52. PubMed ID: 26997369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.
    Omar B; Ahrén B
    Diabetes; 2014 Jul; 63(7):2196-202. PubMed ID: 24962916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion.
    McKillop AM; Stevenson CL; Moran BM; Abdel-Wahab YHA; Flatt PR
    Peptides; 2018 Feb; 100():165-172. PubMed ID: 29412816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
    Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
    Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice.
    Kim SJ; Nian C; Doudet DJ; McIntosh CH
    Diabetes; 2008 May; 57(5):1331-9. PubMed ID: 18299314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Petrov A; Eiermann GJ; Woods J; Zhou YP; Li Z; Zycband E; Feng Y; Zhu L; Roy RS; Howard AD; Li C; Thornberry NA; Zhang BB
    Eur J Pharmacol; 2009 Nov; 623(1-3):148-54. PubMed ID: 19765579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization.
    Shah P; Ardestani A; Dharmadhikari G; Laue S; Schumann DM; Kerr-Conte J; Pattou F; Klein T; Maedler K
    J Clin Endocrinol Metab; 2013 Jul; 98(7):E1163-72. PubMed ID: 23633194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions.
    Sternkopf M; Nagy M; Baaten CCFMJ; Kuijpers MJE; Tullemans BME; Wirth J; Theelen W; Mastenbroek TG; Lehrke M; Winnerling B; Baerts L; Marx N; De Meester I; Döring Y; Cosemans JMEM; Daiber A; Steven S; Jankowski J; Heemskerk JWM; Noels H
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):e65-e77. PubMed ID: 31893947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors.
    Hansotia T; Baggio LL; Delmeire D; Hinke SA; Yamada Y; Tsukiyama K; Seino Y; Holst JJ; Schuit F; Drucker DJ
    Diabetes; 2004 May; 53(5):1326-35. PubMed ID: 15111503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase IV inhibition activates CREB and improves islet vascularization through VEGF-A/VEGFR-2 signaling pathway.
    Samikannu B; Chen C; Lingwal N; Padmasekar M; Engel FB; Linn T
    PLoS One; 2013; 8(12):e82639. PubMed ID: 24349326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DPP IV inhibitor suppresses STZ-induced islets injury dependent on activation of the IGFR/Akt/mTOR signaling pathways by GLP-1 in monkeys.
    Zhang Y; Chen Y; Cheng J; Guo Z; Lu Y; Tian B
    Biochem Biophys Res Commun; 2015 Jan; 456(1):139-44. PubMed ID: 25446112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.